Caprius buys Strax breast center
Caprius of Wilmington, MA, has sealed an acquisition deal with Strax Breast Diagnostic Institute, a breast imaging center in Lauderhill, FL. Strax reported annual revenues of about $1.3 million for 1997 and received about 15,000 patients. The
Caprius of Wilmington, MA, has sealed an acquisition deal with Strax Breast Diagnostic Institute, a breast imaging center in Lauderhill, FL. Strax reported annual revenues of about $1.3 million for 1997 and received about 15,000 patients. The centers modalities include mammography, ultrasound, and stereotactic biopsy. Caprius paid $600,000 for Strax.
The deal represents the next step in Caprius plan to develop a network of breast imaging centers that include its Aurora dedicated breast MRI technology. Caprius also owns a breast imaging center at Faulkner Hospital in Boston and has joint-venture agreements with three U.S. hospitals.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
